{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":" Epigenetics. Synergy. Survival. \ud83e\uddec\ud83d\udc8a\ud83d\udcc8 in  in MYC\/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma","description":"A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC\/BCL2 double-expressor lymphoma. Toxicity was higher but manageable. &amp;nbsp; A quiet but meaningful shift\u2014targeting biology, not just burden. &amp;nbsp; #DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/40999445\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/201134760"}